These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029 [TBL] [Abstract][Full Text] [Related]
7. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635 [TBL] [Abstract][Full Text] [Related]
9. Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661 [TBL] [Abstract][Full Text] [Related]
10. The prognostic value of [ Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131 [TBL] [Abstract][Full Text] [Related]
12. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228 [TBL] [Abstract][Full Text] [Related]
13. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691 [TBL] [Abstract][Full Text] [Related]
14. Predictive value and accuracy of [ Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669 [TBL] [Abstract][Full Text] [Related]
16. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. Wachsmann JW; Ganti R; Peng F Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005 [TBL] [Abstract][Full Text] [Related]
17. Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab. Dittrich D; Pyka T; Scheidhauer K; Lütje S; Essler M; Bundschuh RA Nuklearmedizin; 2020 Jun; 59(3):228-234. PubMed ID: 32259852 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of baseline metabolic tumor volume measured on Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098 [TBL] [Abstract][Full Text] [Related]
19. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma]. Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381 [TBL] [Abstract][Full Text] [Related]
20. Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A Hell J Nucl Med; 2017; 20(3):251-253. PubMed ID: 29177265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]